Rosiglitazone and Fenofibrate Additive Effects on Lipids
Joint Authors
Castillo-Rojas, Luadino M.
Slim, Ahmad M.
Villines, Todd C.
Pearce Moore, Dorette
Slim, Jennifer N.
Hulten, Eddie
Source
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-11-24
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Background.
To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults.
Methods and Results.
Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenofibrate + placebo, rosiglitazone + fenofibrate, or matching double placebo.
The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment.
A total of 548 subjects were screened and 41 met the inclusion criteria.
After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone/fenofibrate groups compared with placebo (P=0.0496).
However, the rosiglitazone only group did not show significant change in triglyceride level.
The change in the Apo AII showed increase in all the treatment groups compared with placebo (P=0.009).
There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone/fenofibrate groups (P=0.0003).
Conclusion.
Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.
American Psychological Association (APA)
Slim, Ahmad M.& Castillo-Rojas, Luadino M.& Hulten, Eddie& Slim, Jennifer N.& Pearce Moore, Dorette& Villines, Todd C.. 2011. Rosiglitazone and Fenofibrate Additive Effects on Lipids. Cholesterol،Vol. 2011, no. 2011, pp.1-4.
https://search.emarefa.net/detail/BIM-460508
Modern Language Association (MLA)
Slim, Ahmad M.…[et al.]. Rosiglitazone and Fenofibrate Additive Effects on Lipids. Cholesterol No. 2011 (2011), pp.1-4.
https://search.emarefa.net/detail/BIM-460508
American Medical Association (AMA)
Slim, Ahmad M.& Castillo-Rojas, Luadino M.& Hulten, Eddie& Slim, Jennifer N.& Pearce Moore, Dorette& Villines, Todd C.. Rosiglitazone and Fenofibrate Additive Effects on Lipids. Cholesterol. 2011. Vol. 2011, no. 2011, pp.1-4.
https://search.emarefa.net/detail/BIM-460508
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-460508